Bill C-393 will save lives, end suffering
Re: "Medicines to Africa: CAMR doesn't need fixing," (The Hill Times, Feb. 28, p. 44). Paul Lucas suggests that fixing CAMR is irrelevant because donations by patent-holding drug companies and competitively priced brand-name drugs are sufficient. He's dead wrong.
SPONSORED CONTENT
Get Weekend Point of View Newsletter
A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
